{"product_id":"tigit-antibody-vstm3-vsig9-bha17116616","title":"TIGIT Antibody \/ VSTM3 \/ VSIG9","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eTIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4+ T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation). It has been demonstrated to be upregulated on T cells in many cancers and is an immuno-oncology target for therapy.\u003c\/p\u003e\u003cp\u003eThis anti-TIGIT antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone TIGIT\/3017, Mouse IgG2c, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e TIGIT\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApplications (listed):\u003c\/strong\u003e ELISA, FACS, IHC-P\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConjugate:\u003c\/strong\u003e Unconjugated\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClone and antibody class:\u003c\/strong\u003e Monoclonal (mouse origin), clone TIGIT\/3017, Mouse IgG2c, kappa\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eBecause antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eTIGIT is referenced in public gene\/protein resources (e.g., UniProt and NCBI Gene), which provide curated names\/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eProfiling TIGIT expression across model systems, perturbations, and time points to support mechanistic hypotheses.\u003c\/li\u003e\n\u003cli\u003eCombining antibody-based detection with multi-omics or imaging readouts to link TIGIT signal with phenotype.\u003c\/li\u003e\n\u003cli\u003eUsing well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eELISA\u003c\/li\u003e\n\u003cli\u003eFACS\u003c\/li\u003e\n\u003cli\u003eIHC-P\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eUse the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecificity considerations:\u003c\/strong\u003e closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControls:\u003c\/strong\u003e include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies and sample context:\u003c\/strong\u003e differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProt Knowledgebase — UniProt — https:\/\/www.uniprot.org\/ - NCBI Gene — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Ensembl Genome Browser — EMBL-EBI — https:\/\/www.ensembl.org\/ - Human Protein Atlas — SciLifeLab\/KTH — https:\/\/www.proteinatlas.org\/ - Gene Ontology — GO Consortium — https:\/\/geneontology.org\/ - Reactome Pathway Database — Reactome — https:\/\/reactome.org\/ - PubMed — NCBI — https:\/\/pubmed.ncbi.nlm.nih.gov\/ --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 100 ug","offer_id":53045178827117,"sku":"V7583-100UG","price":559.0,"currency_code":"USD","in_stock":true},{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 20 ug","offer_id":53045348270445,"sku":"V7583-20UG","price":259.0,"currency_code":"USD","in_stock":true},{"title":"Prediluted in 1X PBS, 0.1 mg\/ml BSA (US sourced), 0.05% sodium azide; *For IHC use only* \/ 7 ml","offer_id":53045348303213,"sku":"V7583IHC-7ML","price":559.0,"currency_code":"USD","in_stock":true},{"title":"1 mg\/ml in 1X PBS; BSA free, sodium azide free \/ 100 ug","offer_id":53045348335981,"sku":"V7583SAF-100UG","price":559.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_75663e8f-536d-46e7-9b1e-b7ee00e3fa41.jpg?v=1771953153","url":"https:\/\/www.ebiohippo.com\/products\/tigit-antibody-vstm3-vsig9-bha17116616","provider":"BioHippo","version":"1.0","type":"link"}